KPJ Healthcare Berhad Just Beat EPS By 49%: Here's What Analysts Think Will Happen Next
KPJ Healthcare Berhad (KLSE:KPJ) just released its half-yearly report and things are looking bullish. The company beat forecasts, with revenue of RM2.2b, some 3.1% above estimates, and statutory earnings per share (EPS) coming in at RM0.024, 49% ahead of expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Following last week's earnings report, KPJ Healthcare Berhad's 15 analysts are forecasting 2026 revenues to be RM4.60b, approximately in line with the last 12 months. Statutory per share are forecast to be RM0.092, approximately in line with the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of RM4.58b and earnings per share (EPS) of RM0.092 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
See our latest analysis for KPJ Healthcare Berhad
There were no changes to revenue or earnings estimates or the price target of RM3.57, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values KPJ Healthcare Berhad at RM4.15 per share, while the most bearish prices it at RM3.05. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that KPJ Healthcare Berhad's revenue growth is expected to slow, with the forecast 4.0% annualised growth rate until the end of 2026 being well below the historical 13% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 11% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than KPJ Healthcare Berhad.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at RM3.57, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for KPJ Healthcare Berhad going out to 2028, and you can see them free on our platform here..
You can also view our analysis of KPJ Healthcare Berhad's balance sheet, and whether we think KPJ Healthcare Berhad is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.